Print
Email

Email

Hims & Hers Health Insider Sold Shares Worth $338,833, According to a Recent SEC Filing

Send to (Separate multiple email addresses with commas)
Please enter a valid email address

Your email address
Please enter a valid email address

Message (Optional)

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Email

Your email has been sent.
Share
Share
Hims & Hers Health Insider Sold Shares Worth $338,833, According to a Recent SEC Filing

Clicking a link will open a new window.
Default text size A
Larger text size A
Largest text size A

Hims & Hers Health Insider Sold Shares Worth $338,833, According to a Recent SEC Filing

, MT Newswires - 4:57 PM ET 4/4/2025 default

04:57 PM EDT, 04/04/2025 (MT Newswires) -- Oluyemi Okupe, Chief Financial Officer, on April 02, 2025, sold 11,581 shares in Hims & Hers Health ( HIMS ) for $338,833. Following the Form 4 filing with the SEC, Okupe has control over a total of 124,104 Class A common shares of the company, with 124,104 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1773751/000177375125000113/xslF345X05/wk-form4_1743799955.xml

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

Hims & Hers Health Insider Sold Shares Worth $338,833, According to a Recent SEC Filing

Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.

Your e-mail has been sent.

BriaCell Subsidiary Develops Antibodies to Anti-Cancer Target B7-H3

MT Newswires - 8 minutes ago
Evercore ISI Adjusts Price Target on Equity Residential to $72 From $76, Keeps In Line Rating

MT Newswires - 8 minutes ago
Evercore ISI Adjusts Price Target on Mid-America Apartment Communities to $152 From $159, Keeps In Line Rating

MT Newswires - 8 minutes ago
Stifel Adjusts Price Target on Philip Morris International to $168 From $160, Maintains Buy Rating

MT Newswires - 8 minutes ago
HSBC Adjusts Price Target on U.S. Bancorp to $54 From $59, Maintains Buy Rating

MT Newswires - 8 minutes ago
BRIEF-Autozone Files For Offering Of Senior Notes Size Not Disclosed

Reuters - 8 minutes ago
CANADA STOCKS-TSX tumbles as Trump's tariff pause rally fades

Reuters - 9 minutes ago
Canadian Dollar Outlook Wildly Uncertain Amid Trump Trade Wars, Says Morningstar

MT Newswires - 9 minutes ago

Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research

These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.